Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;9(7):750-765.
doi: 10.1002/ueg2.12115. Epub 2021 Jun 30.

COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology

Affiliations
Review

COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology

Fernando Magro et al. United European Gastroenterol J. 2021 Sep.

Abstract

Background: The COVID-19 pandemic has created unprecedented challenges in all fields of society with social, economic, and health-related consequences worldwide. In this context, gastroenterology patients and healthcare systems and professionals have seen their routines changed and were forced to adapt, adopting measures to minimize the risk of infection while guaranteeing continuous medical care to chronic patients.

Objective: At this point, it is important to evaluate the impact of the pandemic on this field to further improve the quality of the services provided in this context.

Methods/results/conclusion: We performed a literature review that summarizes the main aspects to consider in gastroenterology, during the pandemic crisis, and includes a deep discussion on the main changes affecting gastroenterology patients and healthcare systems, anticipating the pandemic recovery scenario with future practices and policies.

Keywords: COVID-19; SARS-CoV-2; endoscopy; gastroenterology; inflammatory bowel disease; vaccination.

PubMed Disclaimer

Conflict of interest statement

IR‐L has received financial support for traveling and educational activities from or has served as an advisory board member for MSD, Pfizer, Abbvie, Takeda, Janssen, Tillotts Pharma, Shire Pharmaceuticals, Roche, Celltrion, Faes Farma, Ferring, Dr. Falk Pharma, Otsuka Pharmaceutical, and Adacyte. Financial support for research from Tillotts Pharma.

Figures

FIGURE 1
FIGURE 1
Main changes on the management of IBD patients during the COVID‐19 pandemic. IBD, inflammatory bowel disease; PRO, patient reported outcomes
FIGURE 2
FIGURE 2
COVID‐19 vaccination in inflammatory bowel disease patients. 1Case‐by‐case decision according to comorbidities and risk exposure. 2Within this group of patients: (1) possibility of reduced protection, (2) vaccination not precluded, (3) vaccine booster may be needed, and (4) consider check antibodies after vaccine
FIGURE 3
FIGURE 3
Gastroenterology in the post‐COVID‐19 era

Comment in

Similar articles

Cited by

References

    1. Cui J, Li F, Shi Z‐L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17 (3):181–92. - PMC - PubMed
    1. World Health Organization. COVID‐19 weekly epidemiological update on COVID‐19 ‐ 20 April 2021. 2021. https://www.who.int/publications/m/item/weekly‐epidemiological‐update‐on...
    1. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al‐Jabir A, Iosifidis C, et al. The socio‐economic implications of the coronavirus pandemic (COVID‐19): a review. Int J Surg. 2020;78:185–93. - PMC - PubMed
    1. Montemurro N. The emotional impact of COVID‐19: from medical staff to common people. Brain Behav Immun. 2020;87:23–4. - PMC - PubMed
    1. Ali I, Alharbi OML. COVID‐19: disease, management, treatment, and social impact. Sci Total Environ. 2020;728:138861. - PMC - PubMed

Publication types

MeSH terms